Klivira
Request demo

Streamlining DrChrono Rybelsus Prior Authorization Workflows

Klivira automates DrChrono Rybelsus prior authorization, integrating directly with your DrChrono EHR to accelerate patient access for oral semaglutide prescriptions.

For practices utilizing DrChrono, managing prior authorizations for medications like Rybelsus (oral semaglutide) presents unique challenges, particularly given its novel oral GLP-1 class and typical payer requirements for prior injectable trials. This often leads to manual data entry, delayed approvals, and administrative burden on prior authorization coordinators. Klivira addresses these bottlenecks by seamlessly integrating with DrChrono to automate the entire PA lifecycle.

DrChrono Order Entry and Rybelsus Prior Authorization Flow

When a provider orders Rybelsus within DrChrono, Klivira initiates the prior authorization process. Our integration leverages the DrChrono API and FHIR endpoints to capture prescription details, patient demographics, and relevant clinical data directly from the EHR, eliminating redundant manual data entry and ensuring the PA request is initiated promptly upon order.

Navigating Specialty Pharmacy and Pharmacy Benefit for Rybelsus

As an oral GLP-1 agonist, Rybelsus is typically covered under the pharmacy benefit and often requires dispensing through specialty pharmacies. Klivira's platform supports seamless routing of e-prescriptions (via NCPDP SCRIPT) to the appropriate specialty pharmacy while concurrently managing the associated prior authorization, ensuring all necessary documentation accompanies the prescription for a unified submission.

Clinical Data Extraction for Rybelsus Prior Authorization Support

Klivira's AI-driven engine intelligently extracts critical clinical documentation from DrChrono notes, problem lists, and medication histories to support Rybelsus prior authorization requests. This includes evidence of type 2 diabetes diagnosis, A1C levels, BMI, prior GLP-1 injectable trials (or contraindications), and other payer-specific criteria, directly from the structured and unstructured data within the DrChrono EHR.

DrChrono's Interface with Pharmacy vs. Medical Benefit PAs

For medications like Rybelsus, which fall under the pharmacy benefit, DrChrono's native capabilities for e-prescribing are essential. Klivira augments this by automating the associated ePA submission, often via X12 278 or Da Vinci PAS, ensuring that the PA request aligns with the correct benefit pathway even within DrChrono's ambulatory-focused environment. This distinction is critical for accurate and timely processing.

Klivira's SMART on FHIR and DrChrono Integration for Rybelsus

Klivira integrates with DrChrono using SMART on FHIR standards and the DrChrono API. This robust connection allows for secure, bi-directional data exchange, enabling real-time status updates on Rybelsus prior authorizations directly within the DrChrono workflow. This enhances visibility for PA coordinators and reduces the need to toggle between multiple systems, improving operational efficiency.

Frequently asked questions

How does Klivira handle the 'prior injectable trial' requirement for Rybelsus PAs within DrChrono?

Klivira's platform is configured to identify and extract documentation related to prior injectable GLP-1 trials, or contraindications to such trials, directly from the patient's DrChrono record. This evidence is automatically included in the ePA submission to address payer-specific criteria for Rybelsus approval, minimizing manual review.

Can Klivira help identify if Rybelsus is covered under pharmacy or medical benefit for a DrChrono patient?

While Rybelsus is typically a pharmacy benefit medication, Klivira's process initiates the appropriate ePA pathway based on the drug class and payer rules. Our system is designed to handle the specific requirements for pharmacy benefit PAs, ensuring the request is routed correctly from the DrChrono order, leveraging industry standards like NCPDP SCRIPT and X12 278.

What specific DrChrono data points does Klivira use for Rybelsus PAs?

Klivira pulls key data points such as patient demographics, diagnosis codes (e.g., type 2 diabetes), lab results (e.g., A1C), medication history, and relevant clinical notes detailing treatment rationale and prior therapy attempts. This comprehensive data set, extracted via DrChrono's API, forms the basis of a robust PA submission.

How does Klivira update DrChrono with the PA status for Rybelsus?

Klivira maintains a bi-directional integration with DrChrono. Once a Rybelsus prior authorization is submitted, Klivira tracks its status in real-time. Any updates, including approval, denial, or requests for additional information, are automatically pushed back into the DrChrono patient record, providing PA coordinators with immediate visibility.

Does Klivira support specialty pharmacy communication for Rybelsus orders from DrChrono?

Yes, Klivira supports integrated workflows with specialty pharmacies. Our system ensures that the approved Rybelsus prescription and the associated prior authorization details are transmitted securely to the designated specialty pharmacy, facilitating a smooth fulfillment process for the patient directly from the DrChrono order.

Related coverage

Other drchrono prior auth coverage

Ready to automate prior auth for this integration?

See how Klivira automates prior authorizations for your team.

Request a demo